Carrier-drug conjugate

Details Carrier-drug conjugate Carrier-drug conjugate

2000-06-07

2008-11-04

Russel, Jeffrey E (Department: 1654)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

In an organic compound

C424S009100, C424S009340, C424S009600, C424S085100, C424S649000, C514S002600, C514S008100, C514S021800, C514S034000, C530S363000, C530S408000, C530S409000, C530S410000, C536S006400

Reexamination Certificate

active

07445764

ABSTRACT:
The invention relates to a carrier-drug conjugate comprising a carrier containing a polypeptide sequence having one or several cysteine radicals and a pharmacon containing a pharmaceutical and/or diagnostic active substance, a spacer molecule and a thiol binding group, whereby over 0.7 mol pharmacon per mol of cysteine radical is bound to the carrier by the thiol binding group. The invention also relates to a method for the production of said conjugate and to medicaments and diagnostic kits containing said conjugate.

REFERENCES:
patent: 6124255 (2000-09-01), Schlag et al.
patent: 6310039 (2001-10-01), Kratz
patent: 6706892 (2004-03-01), Ezrin et al.
patent: 7090851 (2006-08-01), Bridon et al.
patent: 7105160 (2006-09-01), Smith
patent: 196 36 889 (1998-03-01), None
patent: 93/08842 (1993-05-01), None
patent: WO 98/10794 (1998-03-01), None
patent: 00 76551 (2000-12-01), None
Kratz et al. A Novel Macromolecular Prodrug Concept . . . Journal of Medicinal Chemistry. Mar. 10, 2000, vol. 43, No. 7, pp. 1253-1256.
Yasuzawa et al. Structural Determination of the Conjugate of Human Serum Albumin with a Mitomycin C Derivative . . . Bioconjugate Chemistry. 1997, vol. 8, No. 3, pp. 391-399.
Daniele Derossi, Gerard Chassaing and Alain Prochiantz; Trojan peptides: the penetratin system for intracellular delivery; trends in Cell Biology (vol. 8) Feb. 1998; 1998 Elsevier Science Ltd.; pp. 84-87.
Willner et al.; (6-Maleimidocaproyl) hydrazone of Doxorubicin-A New Derivative for the Preparation of Immunoconjugates of Doxorubicin; Bioconjugate Chem. 1993, 4, 521-527, pp. 521-527.
Firestone et al.; Synthesis and antitumor activity o f the immunoconjugate BR96-Dox; 1996 Elsevier Science B.V.; Journal of Controlled Release 39 (1996) 251-259.
Kratz et al.; “Preparation, Characterization and In Vitro Efficacy of Albumin Conjugates of Doxorubicin;” Biological & Pharmaceutical Bulletin (of Japan), JP, Pharmaceutical Society of Japan, Bd. 21, Nr. 1, 1998, Seiten 56-61, XP000738275 ISSN: 0918-6158; Abbildung.
A. Trouet et al.; “A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotrope drug-carrier conjugate; In vitro and in vivo studies,” Proceedings of the National Academy of Sciences of USA, Bd. 79, Jan. 1982, Seiten 626-629, XP002161367 Washington US.
S. Netzel-Arnett: “Comparitive sequence specificities of human 72- and 92-kDa gelatinases (type iv Collagenases) and Pump (Matrilysin)” Biochemistry, Bd. 32, Nr. 25, 1993, Seiten 6427-6432, XP002162368 Easton, PA UA.
M. Nichifor et al.; “Macromolecular prodrugs of 5-fluorouracil. 2: Enzymatic degradation.” Journal of Controlled Release, Bd. 39, 1996, Seiten 79-92, XP002162369 Amsterdam NL.
G.M. Dubowchik et al.: “Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin,” Bioorg Med Chem Lett., Bd. 8, Nr. 23, Dec. 1998, Seiten 3341-3346, XP002162370 Seite 3342; Tabelle 1.

Affiliated with

Also associated with

Rating

Carrier-drug conjugate does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Carrier-drug conjugate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Carrier-drug conjugate will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4035330